The number of patients with Alzheimer’s disease (AD) and non-Alzheimer’s disease (non-AD) has drastically increased over recent decades. The amyloid cascade hypothesis attributes a vital role to amyloid-β protein (Aβ) in the pathogenesis of AD. As the main pathological hallmark of AD, amyloid plaques consist of merely the 42 and 40 amino acid variants of Aβ (Aβ42 and Aβ40). The cerebrospinal fluid (CSF) biomarker Aβ42/40 has been extensively investigated and eventually integrated into important diagnostic tools to support the clinical diagnosis of AD. With the development of highly sensitive assays and technologies, blood-based Aβ42/40, which was obtained using a minimally invasive and cost-effective method, has been proven to be abnormal in synchrony with CSF biomarker values. This paper presents the recent progress of the CSF Aβ42/40 ratio and plasma Aβ42/40 for AD as well as their potential clinical application as diagnostic markers or screening tools for dementia.
TakizawaC, ThompsonPL, van WalsemA, FaureC, MaierWC (2015) Epidemiological and economic burden of Alzheimer’s disease: A systematic literature review of data across Europe and the United States of America. J Alzheimers Dis43, 1271–1284.
2.
Alzheimer’s Disease International (2019) World Alzheimer Report 2019. Attitudes to Dementia. Alzheimer’s Disease International, London.
3.
SelkoeDJ (2002) Alzheimer’s disease is a synaptic failure. Science298, 789–791.
4.
JackCR, KnopmanDS, JagustWJ, PetersenRC, WeinerMW, AisenPS, ShawLM, VemuriP, WisteHJ, WeigandSD, LesnickTG, PankratzVS, DonohueMC, TrojanowskiJQ (2013) Tracking pathophysiologi cal processes in Alzheimer’s disease: An updated hypothetica model of dynamic biomarkers. Lancet Neurol12, 207–216.
5.
BondiMW, EdmondsEC, SalmonDP (2017) Alzheimer’s disease: Past, present, and future. J Int Neuropsychol Soc23, 818–831.
WillemseEAJ, TijmsBM, van BerckelBNM, Le BastardN, van der FlierWM, ScheltensP, TeunissenCE (2021) Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. Alzheimers Dement (Amst)13, e12182.
8.
LewczukP, MatzenA, BlennowK, ParnettiL, MolinuevoJL, EusebiP, KornhuberJ, MorrisJC, FaganAM (2017) Cerebrospinal fluid Abeta42/40 corresponds better than Abeta42 to amyloid PET in Alzheimer’s disease. J Alzheimers Dis55, 813–822.
DoeckeJD, WardL, BurnhamSC, VillemagneVL, LiQX, CollinsS, FowlerCJ, ManuilovaE, WidmannM, Rainey-SmithSR, MartinsRN, MastersCL, the AIBL Research Group (2020) Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid PET imaging. Alzheimers Res Ther12, 36.
12.
VandersticheleHM, JanelidzeS, DemeyerL, CoartE, StoopsE, HerbstV, MaurooK, BrixB, HanssonO (2016) Optimized standard operating procedures for the analysis of cerebrospinal fluid Aβ42 and the ratios of Aβ isoforms using low protein binding tubes. J Alzheimers Dis53, 1121–1132.
13.
JanelidzeS, ZetterbergH, MattssonN, PalmqvistS, VandersticheleH, LindbergO, van WestenD, StomrudE, MinthonL, BlennowK; Swedish BioFINDER study group, HanssonO (2016) CSF Aβ42:Aβ40 and Aβ42:Aβ38 ratios: Better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol3, 154–165.
14.
LeuzyA, ChiotisK, HasselbalchSG, RinneJO, de MendoncaA, OttoM, LleoA, BrancoMC, SantanaI, JohanssonJ, StraubSA, von ArnimCAF, BeerA, BlesaJ, ForteaJ, HerukkaSK, PorteliusE, PanneeJ, ZetterbergH, BlennowK, NordbergA (2016) Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study. Brain139, 2540–2553.
15.
JanelidzeS, PanneeJ, MikulskisA, ChiaoP, ZetterbergH, BlennowK, HanssonO (2017) Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment. JAMA Neurol74, 1492–1501.
16.
HanssonO, LehmannS, OttoM, ZetterbergH, LewczukP (2019) Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease. Alzheimers Res Ther11, 34.
17.
AlcoleaD, PeguerolesJ, MuñozL, CamachoV, MoraDL, LeonAF, BastardNL, HuyckE, NadalA, OlmedoV, SampedroF, MontalV, VilaplanaE, ClarimonJ, BlesaR, ForteaJ, LleoA (2019) Agreement of amyloid PET and CSF biomarkers for Alzheimer’s disease on Lumipulse. Ann Clin Transl Neurol6, 1815–1824.
18.
WillemseE, van UffelenK, BrixB, EngelborghsS, VandersticheleH, TeunissenC (2017) How to handle adsorption of cerebrospinal fluid amyloid β (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ42/Aβ40 ratio. Alzheimers Dement13, 885–892.
19.
VerberkIMW, MisdorpEO, KoelewijnJ, BallAJ, BlennowK, DageJL, FandosN, HanssonN, HirtzC, JanelidzeS, KangS, KirmessK, KindermansJ, LeeR, MeyerMR, ShanD, ShawLM, WaligorskaT, WestT, ZetterbergH, EdelmayerRM, TeunissenCE (2022) Characterization of pre-analytical sample handling effects on a panel of Alzheimer’s disease-related blood-based biomarkers: Results from the Standardization of Alzheimer’s Blood Biomarkers (SABB) working group. Alzheimers Dement18, 1484–1497.
20.
DumurgierJ, SchraenS, GabelleA, VercruysseO, BomboisS, LaplancheJ, Peoc’hK, SablonnièreB, KastanenkaKV, DelabyC, PasquierF, TouchonJ, HugonJ, PaquetC, LehmannS (2015) Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: A multicentric study. Alzheimers Res Ther7, 30.
21.
PalmqvistS, InselPS, StomrudE, JanelidzeS, ZetterbergH, BrixB, EichenlaubU, DageJL, ChaiX, BlennowK, MattssonN, HanssonO (2019) Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease. EMBO Mol Med11, e11170.
22.
LewczukP, WiltfangJ, KornhuberJ, VerhasseltA (2021) Distributions of Aβ42 and Aβ42/40 in the cerebrospinal fluid in view of the probability theory. Diagnostics (Basel)11, 2372.
23.
JanelidzeS, StomrudE, PalmqvistS, ZetterbergH, van WestenD, JerominA, SongL, HanlonD, Tan HehirCA, BakerD, BlennowK, HanssonO (2016) Plasma beta-amyloid in Alzheimer’s disease and vascular disease. Sci Rep6, 26801.
24.
OvodV, RamseyKN, MawuenyegaKG, BollingerJG, HicksT, SchneiderT, SullivanM, PaumierK, HoltzmanD M, MorrisJC, BenzingerT, FaganAM, PattersonBW, BatemanRJ (2017) Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement13, 841–849.
25.
SimrénJ, LeuzyA, KarikariTK, HyeA, BenedetAL, RodriguezJL, CarlgrenNM, SchollM, MecocciP, VellasB, TsolakiM, KloszewskaI, SoininenH, LovestoneS, AarslandD, HanssonO, NetoPR, WestmanE, BlennowK, ZetterbergH, AshtonNJ (2021) The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer’s disease. Alzheimers Dement17, 1145–1156.
26.
IinoT, WatanabeS, YamashitaK, TamadaE, HasegawaT, IrinoY, IwanagaS, HaradaA, NodaK, SutoK, YoshidaT (2021) Quantification of amyloid-β in plasma by simple and highly sensitive immunoaffinity enrichment and LC-MS/MS assay. J Appl Lab Med6, 834–845.
27.
FandosN, Pérez-GrijalbaV, PesiniP, OlmosS, BossaM, VillemagneVL, DoeckeJ, FowlerC, MastersCL, SarasaM, AIBL Research Group (2017) Plasma amyloid β42/40 ratios as biomarkers for amyloidβcerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst)8, 179–187.
28.
BenedetAL, BrumWS, HanssonO, Alzheimer’s Disease Neuroimaging Initiative, KarikariTK, ZimmerER, ZetterbergH, BlennowK, AshtonNJ (2022) The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimers Res Ther14, 26.
29.
HaassC, KaetherC, ThinakaranG, SisodiaS (2012) Trafficking and proteolytic processing of APP.a. Cold Spring Harb Perspect Med2, 006270.
30.
MastersCL, SimmsG, WeinmanNA, MulthaupG, McDonaldBL, BeyreutherK (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A82, 4245–4249.
31.
SeubertP, Vigo-PelfreyC, EschF, LeeM, DoveyH, DavisD, SinhaS, SchlossmacherM, WhaleyJ, SwindlehurstC (1992) Isolation and quantification of soluble Alzheimer’s beta-peptide from biological fluids. Nature359, 325–327.
32.
MattssonN, LönneborgA, BoccardiM, BlennowK, HanssonO, Geneva Task Force for the Roadmap of Alzheimer’s Biomarkers (2017) Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging52, 196–213.
33.
MurphyMP, HickmanLJ, EckmanCB, UljonSN, WangR, GoldeTE (1999) γSecretase, evidence for multiple proteolytic activities and influence of membrane positioning of substrate on generation of amyloid βpeptides of varying length. J Biol Chem274, 11914–11923.
34.
JarrettJT, BergerEP, LansburyPT (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer’s disease. Biochemistry32, 4693–4697.
35.
TapiolaT, PirttiläT, MikkonenM, MehtaPD, AlafuzoffI, KoivistoK, SoininenH (2000) Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer’s disease. Neurosci Lett280, 119–122.
36.
LewczukP, EsselmannH, OttoM, MalerJM, HenkelAW, HenkelMK, EikenbergO, AntzC, KrauseWR, ReulbachU, KornhuberJ, WiltfangJ (2004) Neurochemical diagnosis of Alzheimer’s dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging25, 273–281.
37.
MurakamiK, IrieK, OhigashiH, HaraH, NagaoM, ShimizuT, ShirasawaT (2005) Formation and stabilization model of the 42-mer Abeta radical: Implications for the long-lasting oxidative stress in Alzheimer’s disease. J Am Chem Soc127, 15168–15174.
38.
SocherE, StichtH, Horn AnselmH C (2014) The conformational stability of nonfibrillar amyloid-β peptide oligomers critically depends on the C-terminal peptide length. ACS Chem Neurosci5, 161–167.
39.
NathalieP, Jean-NoelO (2008) Processing of amyloid precursor protein and amyloid peptide neurotoxicity. Curr Alzheimer Res5, 92–99.
40.
IwatsuboT, OdakaA, SuzukiN, MizusawaH, NukinaN, IharaY (1994) Visualization of Aβ 42(43) and Aβ 40 in senile plaques with endspecific Aβ monoclonals: Evidence that an initially deposited species is Aβ 42(43). Neuron13, 45–53.
NutuM, ZetterbergH, LondosE, MinthonL, NäggaK, BlennowK, HanssonO, OhrfeltA (2013) Evaluation of the cerebrospinal fluid amyloid-β1-42/amyloid-β1-40 ratio measured by alpha-LISA to distinguish Alzheimer’s disease from other dementia disorders. Dement Geriatr Cogn Disord36, 99–110.
43.
WaragaiM, YoshidaM, MizoiM, SaikiR, KashiwagiK, TakagiK, AraiH, TashiroJ, HashimotoM, IwaiN, UemuraK, IgarashiK (2012) Increased protein-conjugated acrolein and amyloid-β40/42 ratio in plasma of patients with mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis32, 33–41.
44.
MurrayPS, KirkwoodCM, GrayMC, IkonomovicMD, PaljugWR, AbrahamsonEE, HenteleffRA, HamiltonRL, KoflerJK, KlunkWE, LopezOL, PenzesP. , SweetRA(2012)
β-Amyloid 42/40 ratio and Kalirin expression in Alzheimer disease with psychosis. Neurobiol Aging33, 2807–2816.
ShiL, BairdAL, WestwoodS, HyeA, DobsonR, ThambisettyM, LovestoneS (2018) A decade of blood biomarkers for Alzheimer’s disease research: An evolving field, improving study designs, and the challenge of replication. J Alzheimers Dis62, 1181–1198.
SongF, PoljakA, ValenzuelaM, MayeuxR, SmytheGA, SachdevPS (2011) Meta-analysis of plasma amyloid-β levels in Alzheimer’s disease. J Alzheimers Dis6, 365–375.
50.
OlssonB, LautnerR, AndreassonU, ÖhrfeltA, PorteliusE, BjerkeM, HölttäM, RosénC, OlssonC, StrobelG, WuE, DakinK, PetzoldM, BlennowK, ZetterbergH (2016) CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis. Lancet Neurol15, 673–684.
51.
O’BryantSE, GuptaV, HenriksenK, EdwardsM, JerominA, ListaS, BazenetC, SoaresH, LovestoneS, HampelH, MontineT, BlennowK, ForoudT, CarrilloM, Graff-RadfordN, LaskeC, BretelerM, ShawL, TrojanowskiJ Q, SchupfN, RissmanRA, FaganAM, OberoiP, UmekR, WeinerMW, GrammasP, PosnerH, MartinsR, STAR-B and BBBIG working groups (2015) Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research. Alzheimers Dement11, 549–560.
52.
HanssonO, ZetterbergH, VanmechelenE, VandersticheleH, AndreassonU, LondosE, WallinA, MinthonL, BlennowK (2010) Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer’s disease in patients with mild cognitive impairment. Neurobiol Aging31, 357–367.
53.
ChengY, TianDY, WangYJ (2020) Peripheral clearance of brain-derived Aβin Alzheimer’s disease: Pathophysiology and therapeutic perspectives. Transl Neurodegener9, 16.
54.
ZetterbergH, MörtbergE, SongL, ChangL, ProvuncherGK, PatelPP, FerrellE, FournierDR, KanCW, CampbellTG, MeyerR, RivnakAJ, PinkBA, MinnehanKA, PiechT, RissinDM, DuffyDC, RubertssonS, Wilson DavidH, BlennowK (2011) Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloidβlevels in humans. PLoS One6, e28263.
55.
PanneeJ, TörnqvistU, WesterlundA, IngelssonM, LannfeltL, BrinkmalmG, PerssonR, GobomJ, SvenssonJ, JohanssonP, ZetterbergH, BlennowK, PorteliusE (2014) The amyloid-β degradation pattern in plasma–a possible tool for clinical trials in Alzheimer’s disease. Neurosci Lett573, 7–12.
JangH, KimJS, LeeHJ, KimCH, NaDL, KimHJ, AlluéJA, SarasaL, CastilloS, PesiniP, GallacherJ, SeoSW; DPUK (2021) Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort. Alzheimers Res Ther13, 179.
58.
PalmqvistS, JanelidzeS, StomrudE, ZetterbergH, KarlJ, ZinkK, BittnerT, MattssonN, EichenlaubU, BlennowK, HanssonO (2019) Performance of fully automated plasma assays as screening tests for Alzheimer disease-related β-amyloid status. JAMA Neurol76, 1060–1069.
59.
DayanAD (1970) Quantitative histological studies on the aged human brain. II. Senile plaques and neurofibrillary tangles in senile dementia (with an appendix on their occurrence in cases of carcinoma). Acta Neuropathol16, 95–102.
60.
MannDM, YatesPO, MarcyniukB (1984) Alzheimer’s presenile dementia, senile dementia of Alzheimer type and Down’s syndrome in middle age form an age related continuum of pathological changes. Neuropathol Appl Neurobiol10, 185–207.
61.
PriceJL, MorrisJC (1999) Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol45, 358–368.
BeachTG, MonsellSE, PhillipsLE, KukullW (2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol71, 266–273.
64.
LehmannS, DelabyC, BoursierG, CatteauC, GinestetN, TiersL, MaceskiA, NavucetS, PaquetC, DumurgierJ, VanmechelenE, VandersticheleH, GabelleA (2018) Relevance of Aβ42/40 ratio for detection of Alzheimer disease pathology in clinical routine: The PLMR Scale. Front Aging Neurosci10, 138.
65.
BiscettiL, SalvadoriN, FarottiL, CataldiS, EusebiP, PaciottiS, ParnettiL (2019) The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer’s disease. Clin Chim Acta494, 71–73.
66.
LewczukP, LelentalN, SpitzerP, MalerJM, KornhuberJ (2015) Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer’s disease: Validation of two novel assays. J Alzheimers Dis43, 183–191.
67.
SlemmonJR, ShapiroA, MerckenM, StreffderJ, RomanoG, AndreasenN, ZetterbergH, BlennowK (2015) Impact of cerebrospinal fluid matrix on the detection of Alzheimer’s disease with Aβ42 and influence of disease on the total-Aβ42/Aβ40 ratio. J Neurochem135, 1049–1058.
68.
WiltfangJ, EsselmannH, BiblM, HüllM, HampelH, KesslerH, FrölichL, SchröderJ, PetersO, JessenF, LuckhausC, PerneczkyR, JahnH, FiszerM, MalerJM, ZimmermannR, BruckmoserR, KornhuberJ, LewczukP (2007) Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem101, 1053–1059.
69.
JanelidzeS, MattssonN, PalmqvistS, SmithR, BeachTG, SerranoGE, ChaiX, ProctorNK, EichenlaubU, ZetterbergH, BlennowK, ReimanEM, StomrudE, DageJL, HanssonO (2020) Plasma P-tau181 in Alzheimer’s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med26, 379–386.
70.
SacchiL, CarandiniT, FumagalliGG, PietroboniAM, ContarinoVE, SiggillinoS, ArcaroM, FenoglioC, ZitoF, MarottaG, CastellaniM, TriulziF, GalimbertiD, ScarpiniE, ArighiA (2022) Unravelling the association between amyloid-PET and cerebrospinal fluid biomarkers in the Alzheimer’s spectrum disease: Who really deserves an}+?J Alzheimers Dis85, 1009–1020.
PalmqvistS, ZetterbergH, MattssonN, JohanssonP, Alzheimer’s Disease Neuroimaging Initiative, MinthonL, BlennowK, OlssonM, HanssonO, Swedish BioFINDER Study Group (2015) Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology85, 1240–1249.
75.
MattssonN, InselPS, DonohueM, LandauS, JagustWJ, ShawLM, TrojanowskiJQ, ZetterbergH, BlennowK, WeinerMW, Alzheimer’s Disease Neuroimaging Initiative (2015) Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer’s disease. Brain138, 772–783.
76.
HanssonO, BatrlaR, BrixB, CarrilloMC, CorradiniV, EdelmayerRM, EsquivelRN, HallC, LawsonJ, BastardNL, MolinuevoJL, NisenbaumLK, RutzS, SalamoneSJ, TeunissenCE, TraynhamC, UmekRM, VandersticheleH, VandijckM, WahlS, WeberCJ, ZetterbergH, BlennowK (2021) The Alzheimer’s Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau. Alzheimers Dement17, 1575–1582.
BlennowK, ZetterbergH (2019) Fluid biomarker-based molecular phenotyping of Alzheimer’s disease patients in research and clinical settings. Prog Mol Biol Transl Sci168, 3–23.
79.
ShawLM, AriasJ, BlennowK, GalaskoD, MolinuevoJL, SallowayS, SchindlerS, CarrilloMC, HendrixJA, RossA, IllesJudit, RamusC, FiferS (2018) Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease. Alzheimers Dement14, 1505–1521.
80.
LewczukP, ZimmermannR, WiltfangJ, KornhuberJ (2009) Neurochemical dementia diagnostics: A simple algorithm for interpretation of the CSF biomarkers. J Neural Transm116, 1163–1167.
81.
BaldeirasI, SantanaI, LeitãoMJ, VieiraD, DuroD, MroczkoB, KornhuberJ, LewczukP (2019) Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer’s disease. Alzheimers Res Ther11, 2.
82.
LewczukP, KornhuberJ, German Dementia Competence Network, ToledoJB, TrojanowskiJQ, Knapik-CzajkaM, PetersO, WiltfangJ, ShawLM, US-ADNI (2015) Validation of the Erlangen Score algorithm for the prediction of the development of dementia due to Alzheimer’s disease in pre-dementia subjects. J Alzheimers Dis48, 433–441.
83.
SkillbäckT, KornhuberJ, BlennowK, ZetterbergH, LewczukP, the Alzheimer’s Disease Neuroimaging Initiative (2019) Alzheimer’s disease neuroimaging initiative: Erlangen Score predicts cognitive and neuroimaging progression in mild cognitive impairment stage of Alzheimer’s disease. J Alzheimers Dis69, 551–559.
84.
HanssonO, ZetterbergH, BuchhaveP, AndreassonU, LondosE, MinthonL, BlennowK (2007) Prediction of Alzheimer’s disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord23, 316–320.
85.
LewczukP, Lukaszewicz-ZajacM, MroczkoP, KornhuberJ (2020) Clinical significance of fluid biomarkers in Alzheimer’s disease. Pharmacol Rep72, 528–542.
86.
LehmannS, DumurgierJ, SchraenS, WallonD, BlancF, MagninE, BomboisS, BousigesO, CampionD, CretinB, DelabyC, HannequinD, JungB, HugonJ, LaplancheJL, Miguet-AlfonsiC, PeochK, PhilippiN, Quillard-MuraineM, SablonniereB, TouchonJ, VercruysseO, PaquetC, PasquierF, GabelleA (2014) A diagnostic scale for Alzheimer’s disease based on cerebrospinal fluid biomarker profiles. Alzheimers Res Ther6, 38.
87.
LehmannS, DelabyC, BoursierG, CatteauC, GinestetN, TiersL, MaceskiA, NavucetS, PaquetC, DumurgierJ, VanmechelenE, VandersticheleH, GabelleA (2018) Relevance of Aβ42/40 ratio for detection of Alzheimer disease pathology in clinical routine: The PLMR Scale. Front Aging Neurosci10, 138.
88.
MontagneA, ZhaoZ, ZlokovicBV (2017) Alzheimer’s disease: A matter of blood-brain barrier dysfunction?J Exp Med214, 3151–3169.
89.
BielinskaK, RadkowskiM, GrochowskaM, PerlejewskiK, HucT, JaworskaK, MotookaD, NakamuraS, UfnalM (2018) High salt intake increases plasma trimethylamine N-oxide (TMAO) concentration and produces gut dysbiosis in rats. Nutrition54, 33–39.
90.
TzenKY, YangSY, ChenTF, ChengTW, HorngHE, WenHP, HuangYY, ShiueCY, ChiuMJ (2014) Plasma Abeta but not tau is related to brain PiB retention in early Alzheimer’s disease. ACS Chem Neurosci5, 830–836.
91.
KomiR, TanakaF, OmamaS, IshibashiY, TannoK, OnodaT, OhsawaM, TanakaK, OkayamaA, NakamuraM, Iwate-Kenco Study Group (2018) Burden of high blood pressure as a contributing factor to stroke in the Japanese community-based diabetic population. Hypertens Res41, 531–538.
92.
ChiuMJ, YangSY, ChenTF, ChiehJJ, HuangTZ, YipPK, YangHC, ChengTW, ChenYF, HuaMS, HorngHE (2012) New assay for old markers-plasma beta amyloid of mild cognitive impairment and Alzheimer’s disease. Curr Alzheimer Res9, 1142–1148.
WangMJ, YiS, HanJY, ParkSY, JangJW, ChunIK, KimSF, LeeBS, KimGJ, YuJS, LimK, KangSM, ParkYH, YounYC, AnSSA, KimSY (2017) Oligomeric forms of amyloid-beta protein in plasma as a potential blood-based biomarker for Alzheimer’s disease. Alzheimers Res Ther9, 98.
98.
RembachA, WattAD, WilsonWJ, VillemagneVL, BurnhamSC, EllisKA, MaruffP, AmesD, RoweCC, MacaulaySL, BushAI, MartinsRN, MastersCL, DoeckeJD, AIBL Research Group (2014) Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer’s disease as measured by cognitive decline and change in neocortical amyloid burden. Alzheimers Dis40, 95–104.
99.
DoeckeJD, Pérez-GrijalbaV, FandosN, FowlerC, VillemagneVL, MastersCL, PesiniP, SarasaM, AIBL Research Group (2020) Total Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis. Neurology94, e1580–e1591.
100.
Pérez-GrijalbaV, RomeroJ, PesiniP, SarasaL, MonleónI, San-JoséI, ArbizuJ, Martínez-LageP, MunueraJ, RuizA, TárragaL, BoadaM, SarasaM (2019) Plasma Aβ42/40 ratio detects early stages of Alzheimer’s disease and correlates with CSF and neuroimaging biomarkers in the AB255 Study. J Prev Alzheimers Dis6, 34–41.
101.
VerberkIMW, SlotRE, VerfaillieSCJ, HeijstH, PrinsND, van BerckelBNM, ScheltensP, TeunissenCE, van der FlierWM (2018) Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol84, 648–658.
WalterM, WiltfangJ, VogelgsangJ (2020) Pre-analytical sampling and storage conditions of amyloid-β peptides in venous and capillary blood. J Alzheimers Dis78, 529–535.
108.
AshtonNJ, LeuzyA, KarikariTK, Mattsson-CarlgrenN, DodichA, BoccardiM, CorreJ, DrzezgaA, NordbergA, OssenkoppeleR, ZetterbergH, BlennowK, FrisoniGB, GaribottoV, HanssonO (2021) The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. Eur J Nucl Med Mol Imaging48, 2140–2156.
109.
KarantzoulisS, GalvinJE (2011) Distinguishing Alzheimer’s disease from other major forms of dementia. Expert Rev Neurother11, 1579–1591.
110.
ReulS, LohmannH, WiendlH, JohnenA (2017) Can cognitive assessment really discriminate early stages of Alzheimer’s and behavioural variant frontotemporal dementia at initial clinical presentation?Alzheimers Res Ther9, 61.
111.
BousigesO, BlancF (2019) Diagnostic value of cerebro-spinal fluid biomarkers in dementia with Lewy bodies. Clin Chim Acta490, 222–228.
112.
WalkerL, McAleeseKE, ThomasAJ, JohnsonM, Martin-RuizC, ParkerC, CollobySJ, JellingerK, AttemsJ (2015) Neuropathologically mixed Alzheimer’s and Lewy body disease: Burden of pathological protein aggregates differs between clinical phenotypes. Acta Neuropathol129, 729–748.
113.
SchoonenboomNS, ReesinkFE, VerweyNA, KesterMI, TeunissenCE, van de VenPM, PijnenburgYA, BlankensteinMA, RozemullerAJ, ScheltensP, van der FlierWM (2012) Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology78, 47–54.
114.
BayerAJ (2018) The role of biomarkers and imaging in the clinical diagnosis of dementia. Age Ageing47, 641–643.
115.
RizzoG, ArcutiS, CopettiM, AlessandriaM, SavicaR, FontanaA, LiguoriR, LogroscinoG (2018) Accuracy of clinical diagnosis of dementia with Lewy bodies: A systematic review and meta-analysis. J Neurol Neurosurg Psychiatry89, 358–366.
116.
BalasaM, GelpiE, MartínI, AntonellA, ReyMJ, Grau-RiveraO, Sánchez-ValleR, LladóA, the Catalan collaborative Study Group for FTLD (2015) Diagnostic accuracy of behavioral variant frontotemporal dementia consortium criteria (FTDC) in a clinicopathological cohort. Neuropathol Appl Neurobiol41, 882–892.
117.
IrwinDJ, TrojanowskiJQ, GrossmanM (2013) Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer’s disease. Front Aging Neurosci5, 6.
118.
HarrisJM, GallC, ThompsonJC, RichardsonAMT, NearyD, du PlessisD, PalP, MannDWA, SnowdenJS, JonesM (2013) Sensitivity and specificity of FTDC criteria for behavioral variant frontotemporal dementia. Neurology80, 1881–1887.
119.
MendezMF (2009) Frontotemporal dementia: Therapeutic interventions. Front Neurol Neurosci24, 168–178.
120.
BiblM, MollenhauerB, LewczukP, EsselmannH, WolfS, OttoM, KornhuberJ, RütherE, WiltfangJ (2011) Cerebrospinal fluid tau, p-tau 181 and amyloid-beta38/40/42 in frontotemporal dementias and primary progressive aphasias. Dement Geriatr Cogn Disord31, 37–44.
SpiesPE, SlatsD, SjögrenJM, KremerBP, VerheyFR, RikkertMG, VerbeekMM (2010) The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer’s disease from non-Alzheimer’s dementia. Curr Alzheimer Res7, 470–476.
123.
SlaetsS, Le BastardN, MartinJJ, SleegersK, Van BroeckhovenC, De DeynPP, EngelborghsS (2013) Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. J Alzheimers Dis36, 759–767.
124.
VerweyNA, KesterMI, van der FlierWM, VeerhuisR, BerkhofH, TwaalfhovenH, BlankensteinMA, ScheltensAnd P, PijnenburgYA (2010) Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects. J Alzheimers Dis20, 445–452.
125.
SauvéeM, DidierLaurentG, LatarcheC, EscanyéMC, OlivierJL, Malaplate-ArmandC (2014) Additional use of abeta42/abeta40 ratio with cerebrospinal fluid biomarkers P-tau and abeta42 increases the level of evidence of Alzheimer’s disease pathophysiological process in routine practice. J Alzheimers Dis41, 377–386.
StruyfsH, Van BroeckB, TimmersM, FransenE, SleegersK, Van BroeckhovenC, De DeynPP, StrefferJR, MerckenM, EngelborghsS (2015) Diagnostic accuracy of cerebrospinal fluid amyloid-beta isoforms for early and differential dementia diagnosis. J Alzheimers Dis45, 813–822.
128.
PatersonRW, SlatteryCF, PooleT, NicholasJM, MagdalinouNK, ToombsJ, ChapmanMD, LunnMP, HeslegraveAJ, FoianiMS, WestonPSJ, KeshavanA, RohrerJD, RossorMN, WarrenJD, MummeryCJ, BlennowK, FoxNC, ZetterbergH, SchottJM, (2018) Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: Clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alzheimers Res Ther10, 32.
129.
ChaudhryA, HouldenH, RizigM (2020) Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer’s disease: A systematic review. J Neurol Sci415, 116886.
130.
VogelgsangJ, Shahpasand-KronerH, VogelgsangR, StreitF, VukovichR, WiltfangJ (2018) Multiplex immunoassay measurement of amyloid-β42 to amyloid-β40 ratio in plasma discriminates between dementia due to Alzheimer’s disease and dementia not due to Alzheimer’s disease. Exp Brain Res236, 1241–1250.
131.
PalmqvistS, JanelidzeS, QuirozYT, ZetterbergH, LoperaF, StomrudE, SuY, ChenY, SerranoGE, LeuzyA, Mattsson-CarlgrenN, StrandbergO, SmithR, VillegasA, Sepulveda-FallaD, ChaiX, ProctorNK, BeachTG, BlennowK, DageJL, ReimanEM, HanssonO (2020) Discriminative accuracy of plasma phosphotau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA324, 772–781.
LeuzyA, AshtonNJ, Mattsson-CarlgrenN, DodichA, BoccardiM, CorreJ, DrzezgaA, NordbergA, OssenkoppeleR, ZetterbergH, BlennowK, FrisoniGB, GaribottoV, HanssonO (2021) 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. Eur J Nucl Med Mol Imaging48, 2121–2139.
134.
KhalilM, PirpamerL, HoferE, VoortmanMM, BarroC, LeppertD, BenkertP, RopeleS, EnzingerC, FazekasF, SchmidtR, KuhleJ (2020) Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun11, 812.
135.
Mattsson-CarlgrenN, JanelidzeS, PalmqvistS, CullenN, SvenningssonAL, StrandbergO, MengelD, WalshDM, StomrudE, DageJL, HanssonO (2020) Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease. Brain143, 3234–3241.
136.
VergalloA, MégretL, ListaS, CavedoE, ZetterbergH, BlennowK, VanmechelenE, De VosA, HabertMO, PotierMC, DuboisB, NeriC, HampelH, INSIGHT-preAD study group, Alzheimer Precision Medicine Initiative (APMI) (2019) Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer’s disease. Alzheimers Dement15, 764–775.
137.
ToledoJB, VandersticheleH, FigurskiM, AisenPS, PetersenRC, WeinerMW, JackCR, JagustW, DecarliC, TogaAW, ToledoE, XieSX, LeeVM, TrojanowskiJQ, ShawLM, Alzheimer’s Disease Neuroimaging Initiative (2011) Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol122, 401–413.
138.
O’BryantSE, PetersenM, HallJ, JohnsonL, HABS-HD Study Team (2022) Medical comorbidities and ethnicity impact plasma Alzheimer’s disease biomarkers: Important considerations for clinical trials and practice. Alzheimers Dement, doi: 10.1002/alz.12647.
139.
SyrjanenJA, CampbellMR, Algeciras-SchimnichA, VemuriP, Graff-RadfordJ, MachuldaMM, BuG, KnopmanDS, JackCRJr, PetersenRC, MielkeMM (2022) Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement18, 1128–1140.
140.
WallaceSP, CochranSD, DurazoEM, FordCL (2011) The health of aging lesbian, gay and bisexual adults in California. Policy Brief UCLA Cent Health Policy Res (PB2011-2)1–8.
141.
McGovernJ (2014) The forgotten: Dementia and the aging LGBT community. J Gerontol SocWork57, 845–857.
142.
HatzenbuehlerML (2016) Structural stigma: Research evidence and implications for psychological science. Am Psychol71, 742–751.
143.
Fredriksen-GoldsenKI, JenS, BryanAEB, GoldsenJ (2018) Cognitive impairment, Alzheimer’s disease, and other dementias in the lives of lesbian, gay, bisexual and transgender (LGBT) older adults and their caregivers: Needs and competencies. J Appl Gerontol37, 545–569.
144.
CorreroAN, NielsonKA (2020) A review of minority stress as a risk factor for cognitive decline in lesbian, gay, bisexual, and transgender (LGBT) elders. J Gay Lesbian Ment Health24, 2–19.
145.
TeunissenCE, VerberkIMW, ThijssenEH, VermuntL, HanssonO, ZetterbergH, van der FlierWM, MielkeMW, del CampoM (2022) Blood-based biomarkers for Alzheimer’s disease: Towards clinical implementation. Lancet Neurol21, 66–77.
VillemagneVL, BurnhamS, BourgeatP, BrownB, EllisKA, SalvadoO, SzoekeC, MacaulaySL, MartinsR, MaruffP, AmesD, RoweCC, MastersCL, Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group (2013) Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: A prospective cohort study. Lancet Neurol12, 357–367.
150.
BlennowK, DuboisB, FaganAM, LewczukP, de LeonMJ, HampelH (2015) Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease. Alzheimers Dement11, 58–69.
151.
DuaraR, LoewensteinDA, LizarragaG, AdjouadiM, BarkerWW, Greig-CustoMT, RosselliM, PenateA, SheaYF, BeharR, OllarvesA, RobayoC, HansonK, MarsiskeM, BurkeS, Ertekin-TanerN, VaillancourtD, De SantiS, GoldeT, StD (2019) Effect of age, ethnicity, sex, cognitive status and APOE genotype on amyloid load and the threshold for amyloid positivity. Neuroimage Clin22, 101800.
152.
CiarmielloA, GiovanniniE, RiondatoM, GiovacchiniG, DuceV, FerrandoO, De BiasiM, PasseraC, CarabelliE, MannironiA, MansiL, TartaglioneA (2019) Longitudinal cognitive decline in mild cognitive impairment subjects with early amyloid-β neocortical deposition. Eur J Nucl Med Mol Imaging46, 2090–2098.
153.
JohnsonKA, FoxNC, SperlingRA, KlunkWE (2012) Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med2, a006213.
154.
LemercierP, VergalloA, ListaS, ZetterbergH, BlennowK, PotierMC, HabertMO, LejeuneFX, DuboisB, TeipelS, HampelH, INSIGHT-preAD study group and the Alzheimer Precision Medicine Initiative (APMI) (2021) Association of plasma Aβ40/Aβ42 ratio and brain Aβ accumulation: Testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer’s disease. Neurobiol Aging107, 57–69.
155.
HuY, KirmessKM, MeyerMR, RabinoviciGD, GatsonisC, SiegelBA, WhitmerRA, ApgarC, HannaL, KanekiyoM, KaplowJ, KoyamaA, VerbelD, HolubaschMS, KnapikSS, ConnorJ, ContoisJH, JacksonEN, HarpstriteSE, BatemanRJ, HoltzmanDM, VerghesePB, FogelmanI, BraunsteinJB, YarasheskiKE, WestT (2022) Assessment of a plasma amyloid probability score to estimate amyloid positron emission tomography findings among adults with cognitive impairment. JAMA Netw Open5, e228392.
156.
JanelidzeS, TeunissenCE, ZetterbergH, AlluéJA, Sarasa Le, EichenlaubU, BittnerT, OvodV, VerberkIMW, TobaK, NakamuraA, BatemanRJ, BlennowK, HanssonO (2021) Head-to-head comparison of 8 plasma amyloid-β 42/40 assays in Alzheimer disease. JAMA Neurol78, 1375–1382.
157.
KoyamaA, OkerekeOI, YangT, BlackerD, SelkoeDJ, GrodsteinF (2012) Plasma amyloid-beta as a predictor of dementia and cognitive decline: A systematic review and meta-analysis. Arch Neurol69, 824–831.
158.
HilalS, WoltersFJ, VerbeekMM, VandersticheleH, IkramMK, StoopsE, IkramMA, VernooijMW (2018) Plasma amyloid-β levels, cerebral atrophy and risk of dementia: A population-based study. Alzheimers Res Ther10, 63.
159.
van den BoschKA, VerberkIMW, EbenauJL, van der LeeSJ, JansenIE, PrinsND, ScheltensP, TeunissenCE, Van der FlierWM (2021) BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: The SCIENCe project. Neurobiol Aging108, 146–154.
160.
GiudiciKV, de Souto BarretoP, GuyonnetS, LiY, BatemanRJ, VellasB, MAPT/DSA Group (2020) Assessment of plasma amyloid-β42/40 and cognitive decline among community-dwelling older adults. JAMA Netw Open3, e2028634.
161.
OkerekeOI, XiaW, SelkoeDJ, GrodsteinF (2009) Ten-year change in plasma amyloid beta levels and late-life cognitive decline. Arch Neurol66, 1247–1253.
162.
YaffeK, WestonA, Graff-RadfordNR, SatterfieldS, SimonsickEM, YounkinSG, YounkinLH, KullerL, AyonayonHN, DingJ, HarrisTB (2011) Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA305, 261–266.
163.
SullivanKJ, BlackshearC, SiminoJ, TinA, WalkerKA, SharrettAR., YounkinS, GottesmanRF, MielkeMM, KnopmanD, WindhamBG, GriswoldME, MosleyTH (2021) Association of midlife plasma amyloid-β levels with cognitive impairment in late life: The ARIC Neurocognitive Study. Neurology97, e1123–e1131.
164.
PanFF, HuangQ, WangY, WangYF, GuanYH, XieF, GuoQH (2022) Non-linear character of plasma amyloid beta over the course of cognitive decline in Alzheimer’s continuum. Front Aging Neurosci14, 832700.
165.
WangJ, QiaoF, ShangS, LiP, ChenC, DangL, JiangY, HuoK, DengM, WangJ, QuQ (2018) Elevation of plasma amyloid-β level is more significant in early stage of cognitive impairment: A population-based cross-sectional study. J Alzheimers Dis64, 61–69.
166.
SchupfN, TangMX, FukuyamaH, ManlyJ, AndrewsH, MehtaP, RavetchJ, MayeuxR (2008) Peripheral Abeta subspecies as risk biomarkers of Alzheimer’s disease. Proc Natl Acad Sci U S A105, 14052–14057.
167.
PotterR, PattersonBW, ElbertDL, OvodV, KastenT, SigurdsonW, MawuenyegaK, BlazeyT, GoateA, ChottR, YarasheskiK, HoltzmanDM, MorrisJC, BenzingerTL, BatemanRJ (2013) Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med5, 189ra77.
168.
PereiraJB, JanelidzeS, StomrudE, PalmqvistS, van WestenD, DageJL, Mattsson-CarlgrenN, HanssonO (2021) Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. Brain144, 2826–2836.
